Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Lennox Chitsike, Penelope J. Duerksen-Hughes
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Vivek P. Chavda, Rajashri Bezbaruah, Kangkan Deka, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1926-1926
Open Access | Times Cited: 71
Spike protein mediated membrane fusion during SARS‐CoV‐2 infection
Xinyu Li, Huijun Yuan, Xiaozhen Li, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 42
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
Khan Sharun, Ruchi Tiwari, Mohd I. Yatoo, et al.
Narra J (2022) Vol. 2, Iss. 3, pp. e92-e92
Open Access | Times Cited: 34
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access
A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.
Yasser Mohamed, Yousra A. El‐Maradny, Ahmed K. Saleh, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113499-113499
Open Access | Times Cited: 22
Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides
George N. Llewellyn, Hsu-Yu Chen, Geoffrey L. Rogers, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access | Times Cited: 12
Efficacy and Safety of Corticosteroid Regimens for the Treatment of Hospitalized COVID-19 Patients: A meta-analysis
Fangwen Zhou, Jiawen Deng, Kiyan Heybati, et al.
Future Virology (2022) Vol. 17, Iss. 7, pp. 463-489
Open Access | Times Cited: 19
Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated review
Saba Zanganeh, Nima Goodarzi, Mohammad Doroudian, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 4
Closed Access | Times Cited: 23
The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics
Friederike Eilts, Sarah Bauer, Keith Fraser, et al.
Carbohydrate Polymers (2022) Vol. 299, pp. 120167-120167
Open Access | Times Cited: 14
Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2
Davide Gentile, Lucia Chiummiento, Alessandro Santarsiere, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 338-338
Open Access | Times Cited: 2
Recreating the biological steps of viral infection on a cell-free bioelectronic platform to profile viral variants of concern
Zhongmou Chao, Ekaterina Selivanovitch, Konstantinos Kallitsis, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Potential therapeutic applications of extracellular vesicles in the immunopathogenesis of COVID-19
Morteza Motallebnezhad, Melody Omraninava, Hadi Esmaeili Gouvarchin Ghaleh, et al.
Pathology - Research and Practice (2022) Vol. 241, pp. 154280-154280
Open Access | Times Cited: 13
Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection
Rafaela Milan Bonotto, Ana Mitrović, Izidor Sosič, et al.
Antiviral Research (2023) Vol. 216, pp. 105655-105655
Open Access | Times Cited: 7
Engineering defensin α‐helix to produce high‐affinitySARS‐CoV‐2 spike protein binding ligands
Leonardo Antônio Fernandes, Anderson Gomes, B.G. Guimarães, et al.
Protein Science (2022) Vol. 31, Iss. 6
Open Access | Times Cited: 9
A review on computational approaches that support the researches on traditional Chinese medicines (TCM) against COVID-19
Chattarin Ruchawapol, Wenwei Fu, Hong‐Xi Xu
Phytomedicine (2022) Vol. 104, pp. 154324-154324
Open Access | Times Cited: 9
Unraveling the enigma: The emerging significance of pulmonary surfactant proteins in predicting, diagnosing, and managing COVID‐19
Mohammad‐Navid Bastani, Shahram Jalilian
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 6
Open Access | Times Cited: 1
The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS‐CoV‐2 infection in cultured human lung cells
Michael J. Houghton, Églantine Balland, Matthew J. Gartner, et al.
BioFactors (2024) Vol. 50, Iss. 6, pp. 1268-1286
Open Access | Times Cited: 1
ACE2 : S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics
Lennox Chitsike, John L. Krstenansky, Penelope J. Duerksen-Hughes
Advances in Pharmacological and Pharmaceutical Sciences (2021) Vol. 2021, pp. 1-10
Open Access | Times Cited: 12
The RAAS Axis and SARS-CoV-2: From Oral to Systemic Manifestations
Minela Aida Mărănducă, Calin George Vamesu, Daniela Maria Tănase, et al.
Medicina (2022) Vol. 58, Iss. 12, pp. 1717-1717
Open Access | Times Cited: 8
Novel Polymyxin-Inspired Peptidomimetics Targeting the SARS-CoV-2 Spike:hACE2 Interface
Kelly Bugatti, Andrea Sartori, Lucia Battistini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8765-8765
Open Access | Times Cited: 4
Impact of the COVID-19 vaccine booster strategy on vaccine protection: a pilot study of a military hospital in Taiwan
Yuli Wang, Shu-Tsai Cheng, Ching‐Fen Shen, et al.
Clinical and Experimental Vaccine Research (2023) Vol. 12, Iss. 4, pp. 337-337
Open Access | Times Cited: 4
Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1
Ji Youn Youn, Jian Wang, Qian Li, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 6
Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides
George N. Llewellyn, Hsu-Yu Chen, Geoffrey L. Rogers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
SARS-CoV-2 spike and ACE2 entanglement-like binding
Massimo Pregnolato, Paola Zizzi
Quantum Machine Intelligence (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 2
Current diagnostic and therapeutic approaches for severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) and the role of nanomaterial-based theragnosis in combating the pandemic
Beibei Zhang, Qiulan Wu, Liping Yin, et al.
Nanotechnology Reviews (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top